share_log

Helius Medical Technologies, Inc. Announces Partnership With Lovell Government Services to Expand Reach of PoNS Therapy

Helius Medical Technologies, Inc. Announces Partnership With Lovell Government Services to Expand Reach of PoNS Therapy

Helius Medical Technologies, Inc. 宣佈與洛弗爾政府服務部門合作,以擴大 PonS 療法的覆蓋範圍
Benzinga ·  04/03 19:08

Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced it has partnered with Lovell Government Services ("Lovell"), an SBA-certified Service Disabled Veteran Owned Small Business ("SDVOSB"), to make the Company's Portable Neuromodulation Stimulator ("PoNS") device available to federal healthcare systems. PoNS is indicated in the U.S. for use as a short-term treatment of gait deficit in adults with mild-to-moderate symptoms from MS when used in conjunction with physical therapy.

專注於爲平衡和步態缺陷提供新型治療性神經調節方法的神經科技公司Helius Medical Technologies, Inc.(納斯達克股票代碼:HSDT)(“Helius” 或 “公司”)今天宣佈,它已與經SBA認證的殘疾退伍軍人所屬服務小型企業(“SDVOSB”)合作生產該公司的便攜式神經系統聯邦醫療保健系統可以使用調製刺激器(“PonS”)設備。在美國,當與物理療法結合使用時,PonS可用作短期步態缺陷治療有輕度至中度多發性硬化症症狀的成年人的步態缺陷。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論